Approach to patients with liver diseases
Authors:
Radan Brůha
Authors‘ workplace:
IV. interní klinika 1. LF UK a VFN Praha, přednosta prof. MUDr. Aleš Žák, DrSc.
Published in:
Vnitř Lék 2015; 61(Suppl 4): 6-12
Category:
Reviews
Overview
In recent years the most frequent cause of chronic liver diseases in western countries has become Non-alcoholic hepatic steatosis/steatohepatitis (NAFLD/NASH). It is part or immediate manifestation of metabolic syndrome. A crucial task for the future is to diagnose this hepatic injury to a greater extent and cooperate with other internal medicine physicians in the care of patients with NAFLD. It has been clearly proven that it is not a benign disease, as assumed in the past. Non-alcoholic steatohepatitis can have serious consequences for the patient and it needs to be actively searched for. The still prevalent notion that normal liver tests in patients with hepatic steatosis eliminate a more serious liver injury has also been disproved. On the contrary, this condition is common in patients with NAFLD. Also the patients with normal liver test results can have advanced fibrosis/cirrhosis. It is needed to target identification of a liver injury in a patient with the detected metabolic syndrome with the same intensity as the other diabetes complications are searched for today. All patients with type 2 diabetes mellitus (DM2T) should undergo ultrasound examination of the liver and it is further recommended to check the liver tests in annual intervals at least. The cause of liver lesions should be found in all diabetics who had higher liver test values established even once. The liver injury needs to be further regularly followed in these patients. Regarding the patients without the metabolic syndrome anamnesis with the NAFLD signs, it is needed to actively search for the components of the metabolic syndrome (hypertension, dyslipidemia, impaired glucose tolerance, diabetes).
Key words:
alcoholic liver injury – cirrhosis – liver fibrosis – metabolic syndrome – NAFLD – non-alcoholic hepatic steatosis.
Sources
1. Blachier M, Leleu H, Peck-Radosavljevic M et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013; 58(3): 593–608.
2. Kim HC, Nam CM, Jee SH et al. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328(7446): 983.
3. Ehrmann J, Hůlek P (eds) et al. Hepatologie. Grada Publishing: Praha 2010. 616 s. ISBN 978–80–247–3118–6. 4.
4. Gilmore IT, Burroughs A, Murray-Lyon IM et al. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36(3): 437–441.
5. Wieckowska A, Mc Cullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007; 46(2): 582–589.
6. Sandrin L, Fourquet B, Hasquenoph JM et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29(12): 1705–1713.
7. Rifai K, Cornberg J, Mederacke I et al. Clinical feasibility of liver elastography by acoustic radiation force impulse imaging (ARFI). Dig Liver Dis 2011; 43(6): 491–497.
8. Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011; 60(7): 977–984.
9. Poynard T, Lebray P, Ingiliz P et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40. Dostupné z DOI: <http://doi: 10.1186/1471–230X-10–40>.
10. Zatonski WA, Sulkowska U, Manczuk M et al. Liver cirrhosis mortality in Europe, with special attention to Central and Eastern Europe. Eur Addict Res 2010; 16(4): 193–201.
11. Bosetti C, Levi F, Lucchini F et al. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 2007; 46(5): 827–839.
12. Bellentani S, Saccoccio G, Costa G et al. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41(6): 845–850.
13. Snow WM, Murray R, Ekuma O et al. Alcohol use and cardiovascular health outcomes: a comparison across age and gender in the Winnipeg Health and Drinking Survey Cohort. Age Ageing 2009; 38(2): 206–212.
14. Bhattacharya R, Shuhart MC. Hepatitis C and alcohol: interactions, outcomes, and implications. J Clin Gastroenterol 2003; 36(3): 242–252.
15. Raynard B, Balian A, Fallik D et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002; 35(3): 635–638.
16. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346(16): 1221–1231.
17. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37(3): 917–923.
18. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35(2): 373–379.
19. Tuyama AC, Chang CY. Non-alcoholic fatty liver disease. J Diabetes 2012; 4(3): 266–280.
20. Bellentani S, Bedogni G, Miglioli L et al. The epidemiology of fatty liver. Eur J Gastroenterol Hepatol 2004; 16(11): 1087–1093.
21. Hilden M, Christoffersen P, Juhl E et al. Liver histology in a „normal“ population – examinations of 503 consecutive fatal traffic casualties. Scand J Gastroenterol 1977; 12(5): 593–597.
22. Dvorak K, Hainer R, Petrtyl J et al. The prevalence of nonalcoholic liver steatosis in patients with type 2 diabetes mellitus in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2015; 159(3): 442–448.
23. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129(1): 113–121.
24. Caldwell S, Argo C. The natural history of non-alcoholic fatty liver disease. Dig Dis 2010; 28(1): 162–168.
25. Baumeister SE, Völzke H, Marschall P et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 2008; 134(1): 85–94.
26. Yeh MM, Brunt EM. Pathological features of fatty liver disease. Gastroenterology 2014; 147(4): 754–764.
27. Haflidadottir S, Jonasson JG, Norland H et al. Long-term follow-up and liver-related death rate in patients with non-alcoholic and alcoholic related fatty liver disease. BMC Gastroenterol 2014; 14: 166. Dostupné z DOI: <http://doi: 10.1186/1471–230X-14–166>.
28. Barrio E, Tome S, Rodriguez I et al. Liver disease in heavy drinkers with and without alcohol withdrawal syndrome. Alcohol Clin Exp Res 2004; 28(1): 131–136.
29. Reeves HL, Burt AD, Wood S et al. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996; 25(6): 677–683.
30. Teli MR, Day CP, Burt AD et al. Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet 1995; 346(8981): 987–990.
31. Ludwig J, Viggiano TR, Mc Gill DB et al. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55(7): 434–438.
32. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116(16): 1413–1419.
33. Hultcrantz R, Glaumann H, Lindberg G et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. Scand J Gastroenterol 1986; 21(1): 109–113.
34. Pinto HC, Baptista A, Camilo ME et al. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996; 41(1): 172–179.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2015 Issue Suppl 4
Most read in this issue
- Cirrhosis of the liver and HCV
- Approach to patients with liver diseases
- Possibilities of IFN-free therapy of hepatitis C